Birchview Capital, LP
Long book
$175.7M
Q1 2026
Positions
73
Top-10 weight
55%
concentration
Last quarter
+23.7%
SPY +14.8%
Turnover
34%
of book per quarter
Strategy in plain words
auto-generated from filingsBirchview Capital, LP is a diversified fundamental manager, specialised in healthcare (68% of the long book), running a $175.7M US long book across 73 positions.
The portfolio is concentrated: the top 10 names carry 55% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: KLA CORP, BRISTOL-MYERS SQUIBB CO, COMPASS THERAPEUTICS INC, LAM RESEARCH CORP, STOKE THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 1.2pp per quarter ahead of the S&P 500, beating the index in 6 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-7.9%
Q2 2024
+14.5%
Q3 2024
+3.3%
Q4 2024
-5.1%
Q1 2025
-14.8%
Q2 2025
+19.6%
Q3 2025
+13.8%
Q4 2025
+3.8%
Q1 2026
+23.7%
Sector allocation
Healthcare 65%
Other 19%
Materials 6%
Energy 5%
Industrials 5%
Services media 0%
Long book by quarter
What does Birchview Capital, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| KLAC KLA CORP | Other | 19.9K | $29.3M | 16.7% | -9.1% |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 306.3K | $18.6M | 10.6% | +1.1% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 1.5M | $7.8M | 4.4% | -8.0% |
| LRCX LAM RESEARCH CORP | Industrials | 36.0K | $7.7M | 4.4% | -10.7% |
| STOK STOKE THERAPEUTICS INC | Healthcare | 210.0K | $6.8M | 3.9% | -19.2% |
| OVV OVINTIV INC | Energy | 107.5K | $6.4M | 3.6% | Held |
| NTLA INTELLIA THERAPEUTICS INC | Materials | 445.4K | $5.7M | 3.3% | +41.2% |
| SLDB SOLID BIOSCIENCES INC | Healthcare | 626.0K | $4.5M | 2.6% | -11.3% |
| PRTA PROTHENA CORP PLC | Healthcare | 449.0K | $4.4M | 2.5% | +1.8% |
| BDSX BIODESIX INC | Healthcare | 286.8K | $4.2M | 2.4% | Held |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 171.0K | $3.8M | 2.2% | Held |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 35.0K | $3.7M | 2.1% | -36.4% |
| NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 27.2K | $3.6M | 2.0% | Held |
| OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 219.0K | $3.3M | 1.9% | -18.6% |
| RLMD RELMADA THERAPEUTICS INC | Healthcare | 409.4K | $2.8M | 1.6% | New |
| OCUL OCULAR THERAPEUTIX INC | Healthcare | 320.0K | $2.7M | 1.5% | New |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 4.5K | $2.7M | 1.5% | +50.0% |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 31.0K | $2.2M | 1.3% | Held |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 70.1K | $2.2M | 1.3% | New |
| NVCR NOVOCURE LTD | Healthcare | 202.3K | $2.2M | 1.3% | +33.0% |
| EQT EQT CORP | Energy | 34.6K | $2.2M | 1.3% | Held |
| PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 195.0K | $2.2M | 1.2% | Held |
| PACB PACIFIC BIOSCIENCES OF CALIF | Healthcare | 1.5M | $2.0M | 1.1% | +200.0% |
| CYTK CYTOKINETICS INC | Healthcare | 30.0K | $2.0M | 1.1% | Held |
| CORT CORCEPT THERAPEUTICS INC | Healthcare | 47.2K | $1.9M | 1.1% | -29.8% |
| VERA VERA THERAPEUTICS INC | Healthcare | 44.0K | $1.8M | 1.0% | Held |
| ALKS ALKERMES PLC | Healthcare | 50.0K | $1.8M | 1.0% | Held |
| ENGN enGene Therapeutics Inc | Healthcare | 250.0K | $1.7M | 1.0% | New |
| QURE UNIQURE NV | Healthcare | 100.7K | $1.6M | 0.9% | +227.1% |
| ZBIO ZENAS BIOPHARMA INC | Healthcare | 70.0K | $1.4M | 0.8% | New |
| QDEL QUIDELORTHO CORP | Materials | 82.5K | $1.4M | 0.8% | +13.8% |
| FHTX FOGHORN THERAPEUTICS INC | Healthcare | 281.7K | $1.3M | 0.8% | Held |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 62.0K | $1.3M | 0.7% | Held |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 21.0K | $1.2M | 0.7% | Held |
| 4XC1 KALVISTA PHARMACEUTICALS INC | — | 57.0K | $1.1M | 0.7% | Held |
| IMNM IMMUNOME INC | Healthcare | 50.0K | $1.1M | 0.6% | -61.5% |
| FCX FREEPORT-MCMORAN INC | Materials | 18.0K | $1.1M | 0.6% | 0.0% |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 6.0K | $1.0M | 0.6% | -1.0% |
| BIIB BIOGEN INC | Healthcare | 5.0K | $917K | 0.5% | New |
| LPCN LIPOCINE INC | Healthcare | 111.8K | $893K | 0.5% | New |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 29.2K | $868K | 0.5% | -32.1% |
| HROW HARROW INC | Healthcare | 24.0K | $846K | 0.5% | -29.4% |
| PHVS PHARVARIS NV | Healthcare | 29.8K | $843K | 0.5% | Held |
| VSTM VERASTEM INC | Healthcare | 150.0K | $795K | 0.5% | Held |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 9.0K | $758K | 0.4% | -43.8% |
| HALO HALOZYME THERAPEUTICS INC | Healthcare | 10.1K | $653K | 0.4% | Held |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 8.7K | $645K | 0.4% | Held |
| APLSUSD APELLIS PHARMACEUTICALS INC | — | 14.0K | $563K | 0.3% | Held |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 16.9K | $562K | 0.3% | New |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 25.9K | $559K | 0.3% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 73 | $175.7M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 68 | $170.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 69 | $132.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 71 | $100.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 68 | $115.2M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR/ANEW HOLDINGS | Jun 30, 2025 | 68 | $122.9M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 68 | $122.7M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR/ANEW HOLDINGS | Jun 30, 2025 | 62 | $115.5M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 62 | $115.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR/ANEW HOLDINGS | Jun 30, 2025 | 61 | $108.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 61 | $108.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR/ANEW HOLDINGS | Jun 30, 2025 | 60 | $122.7M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 60 | $122.5M | canonical | SEC ↗ |